Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?
OBJECTIVE
The objective of this study was to investigate whether follicle stimulating hormone (FSH), anti-Mullerian hormone (AMH) and inhibin B could be useful in predicting the ovarian response to gonadotrophin stimulation in assisted reproduction patients who are considered to be poor responders.


METHODS
Prospective study.


METHODS
Fertility unit.


METHODS
Blood samples were collected on day five or six in the early follicular phase of an untreated menstrual cycle. Samples were collected from 69 patients.


METHODS
Serum samples were assayed for FSH, AMH and inhibin B using commercial immunoassay kits.


METHODS
Response to gonadotrophin stimulation and number of eggs collected.


RESULTS
Among the 69 patients, 52 patients completed an IVF cycle and 17 patients had to cancel the cycle because of poor ovarian response to gonadotrophin stimulation. Mean FSH levels were significantly higher (P < 0.05) in the cancelled group (10.69 +/- 2.27 mIU/mL) compared with the cycle-completed group (7.89 +/- 0.78 mIU/mL). Mean AMH levels were significantly lower (P < 0.01) in the cancelled group (0.175 +/- 0.04 ng/mL) compared with the cycle-completed group (1.13 +/- 0.2 ng/mL). Mean inhibin B levels were significantly lower (P < 0.001) in the cancelled group (70 +/- 12.79 pg/mL) compared with the completed group (126.9 +/- 8.8 pg/mL). Predictive statistics show that AMH is the best single marker and that the combination of FSH, AMH and inhibin B is modestly better than the single marker. Linear regression analysis in the cycle completed patients shows that although FSH (r= 0.25, P < 0.05) and inhibin B (r= 0.35, P < 0.05) have a significant linear association with the number of eggs collected, AMH has the greatest association (r= 0.69, P < 0.001) with the number of eggs collected among the parameters measured.


CONCLUSIONS
In this particular group of IVF patients, AMH is the best single marker of ovarian response to gonadotrophin stimulation. The combined markers modestly improved the prediction.
Muttukrishna
Shanthi
S
Department of Obstetrics and Gynaecology, RFUCL Medical School, University College London, 86-96 Chenies Mews, London WC1E 6HX, UK.
Suharjono
Harris
H
McGarrigle
Hugh
H
Sathanandan
Muttukrishna
M
D000328:Adult; D054304:Anti-Mullerian Hormone; D015415:Biomarkers / Q000097:blood; D015536:Down-Regulation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D006023:Glycoproteins / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000097:blood*; D006801:Humans; D007265:Inhibins / Q000097:blood*; D008875:Middle Aged; D010062:Ovulation Induction; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D020554:Sperm Injections, Intracytoplasmic; D013735:Testicular Hormones / Q000097:blood*
D015415:Biomarkers; D006023:Glycoproteins; D013735:Testicular Hormones; C422364:inhibin B; D007987:Gonadotropin-Releasing Hormone; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D005640:Follicle Stimulating Hormone